Check out our H1 2024 Newsletter
Discover the latest on our leading imaging agent, Zr89 crefmirlimab berdoxam (CD8 ImmunoPET™), through recent publications and conferences. See Phase II study updates, upcoming events, and more. A special thanks to our Key Collaborators for their pivotal role in advancing our research and data.